Stories abound of people who were subjected to remdesivir and ventilation, without proper informed consent, sometimes even against their will. Other accounts tell of judges having to issue orders for patients to be allowed to try IVM and HCQ in hospital, despite the safety profile and lack of contraindications with other drugs – meaning, it couldn’t hurt to try and it might help.
Gilead, flush with the prospect of remdesivir becoming the treatment for Covid, predicted remdesivir would bring in $3.5 billion in 2020 alone.
Before Fauci's remdesivir study was completed, a study conducted in China was released that should have put remdesivir out of the running.
Fauci, knowing the Chinese study was about to be published, which would likely impede the FDA's approval of remdesivir to treat Covid-19, headed off the bad news in an Oval Office press conference on April 21, 2020 declaring "Quite good news." Fauci said the NIAID's clinical trial showed remdesivir was reducing the hospital stay of infected Covid patients by about four days.
Fauci said he was ending the study, would give remdesivir to the placebo group, and that remdesivir would be America's new "Standard of care" for Covid.
Undeterred, the NIH issued a News Release stating that the "NIH clinical trial shows Remdesivir accelerates recovery from advanced Covid-19." Two days later on May 1, 2020 the FDA made remdesivir the official new Emergency Use Authorized Covid drug.
Although trial data and actual field experience were showing that remdesivir did not improve outcomes for hospitalized Covid patients, remdesivir was given full FDA approval in October 2020.
In granting approval, the FDA cited Fauci's NIH study, and also approved remdesivir for use in pediatric patients 12 years and older, based on a small study sponsored by remdesivir manufacturer Gilead Sciences.
No comments:
Post a Comment